Динамика неврологического статуса и мозгового нейротрофического фактора у больных рассеянным склерозом на фоне терапии финголимодом и моноклональными антителами
Е Л Медведева, Т. В. Байдина · Современные проблемы науки и образования · 2015
The influence of 6-month monoclonal antibody (natalizumab) and fingolimod (gileniya) therapy on the clinical course of multiple sclerosis (MS) and on the concentration of brain-derived neurotrophic factor (BDNF) in serum was investigated. It was determined that these kinds of therapy significantly improve neurological status of the patients, both variants of therapy improve the mobility of the brush (the second component of MSFC), therapy with natalizumab improves the overall score of EDSS. Treatment with both of these drugs reduce physical fatigue. Fingolimod therapy also improves the physical component of quality of life. Monoclonal antibody and fingolimod treatment do not stimulate mechanisms of neurotrophic protection, concentration of BDNF in the serum during such treatment is decreased. The additional medication with neurotrophic drugs can improve the results of treatment of patients with MS.
Cited by 0 works.